All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-12-29T14:32:36.000Z

Which patients should be considered for allo-HSCT?

Dec 29, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in acute myeloid leukemia.

During the AML Hub Steering Committee meeting, held on November 15, 2023, key opinion leaders met to discuss which patients should be considered for allogenic hematopoietic stem cell transplantation. This discussion was chaired by Charles Craddock and featured Jefferey Lancet, Roland Walter, Jorge Sierra, Gail Roboz, and Gert Ossenkoppele.

Which patients should be considered for allo-HSCT?

Charles Craddock discussed the optimization of transplant outcomes and highlighted key data from several recent studies. The steering committee considered factors that may impact transplant outcomes and the need to optimize patient status before transplant. They also discussed treatment decisions in older/unfit patients and explored factors to consider when deciding whether to proceed to transplant or pursue ongoing maintenance therapy.

More about...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox